535 related articles for article (PubMed ID: 6430642)
21. Laboratory criteria for menopause in women using oral contraceptives.
Creinin MD
Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
[TBL] [Abstract][Full Text] [Related]
22. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
Lemay A; Dewailly SD; Grenier R; Huard J
J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
[TBL] [Abstract][Full Text] [Related]
23. Comparison of contraceptive acceptability of levonorgestrel and ethinyl oestradiol administered in one three-phasic (Trionetta) and one monophasic (Neovletta) version.
Carlborg L
Contraception; 1983 May; 27(5):439-52. PubMed ID: 6349925
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate.
Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E
Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759
[TBL] [Abstract][Full Text] [Related]
25. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment.
Elomaa K; Lähteenmäki P
Contraception; 1999 Nov; 60(5):275-9. PubMed ID: 10717779
[TBL] [Abstract][Full Text] [Related]
26. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
27. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
[TBL] [Abstract][Full Text] [Related]
28. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills.
Alvarez F; Faundes A; Johansson E; Coutinho E
Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876
[TBL] [Abstract][Full Text] [Related]
29. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest.
Spona J; Feichtinger W; Kindermann C; Moore C; Mellinger U; Walter F; Gräser T
Contraception; 1997 Sep; 56(3):185-91. PubMed ID: 9347211
[TBL] [Abstract][Full Text] [Related]
30. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
van Heusden AM; Fauser BC
Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
[TBL] [Abstract][Full Text] [Related]
31. The effect of norethisterone (500 mcg) and ethinyl estradiol (35 mcg) capsules on the pituitary-ovarian axis.
Nuttall ID; Elstein M; Fahmy DR
Contraception; 1982 May; 25(5):463-9. PubMed ID: 6809424
[TBL] [Abstract][Full Text] [Related]
32. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
Xiao B; Zeng T; Wu S; Sun H; Xiao N
Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
[TBL] [Abstract][Full Text] [Related]
33. LH, FSH, estradiol and progesterone levels after discontinuation of hormonal contraception.
Balogh A; Ditrói F; Lampé LG
Acta Univ Palacki Olomuc Fac Med; 1981; 101():95-101. PubMed ID: 6242699
[TBL] [Abstract][Full Text] [Related]
34. Cyclic fluctuations in human serum lipid and apolipoprotein levels during the normal menstrual cycle: comparison with changes occurring during oral contraceptive therapy.
Lussier-Cacan S; Xhignesse M; Desmarais JL; Davignon J; Kafrissen ME; Chapdelaine A
Metabolism; 1991 Aug; 40(8):849-54. PubMed ID: 1907348
[TBL] [Abstract][Full Text] [Related]
35. Studies on low dose oral contraceptives: plasma hormone changes in relation to deliberate pill ('Microgynon 30') omission.
Morris SE; Groom GV; Cameron ED; Buckingham MS; Everitt JM; Elstein M
Contraception; 1979 Jul; 20(1):61-9. PubMed ID: 477318
[TBL] [Abstract][Full Text] [Related]
36. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
37. The short-term effects of a low-dose oral contraceptive on glucose metabolism, plasma lipids and blood clotting factors.
Skouby SO; Wagner HH; Andersen O
Contraception; 1983 Nov; 28(5):489-99. PubMed ID: 6425010
[TBL] [Abstract][Full Text] [Related]
38. Ovulation inhibition with a combined oral contraceptive containing 20 micrograms ethinyl estradiol and 250 micrograms levonorgestrel. Serum levels of the active ingredients and FSH, LH, estradiol 17-beta and progesterone.
Lunell NO; Carlström K; Zador G
Acta Obstet Gynecol Scand Suppl; 1979; 88():17-21. PubMed ID: 294110
[TBL] [Abstract][Full Text] [Related]
39. Ovarian function during treatment with high ratio levonorgestrel/ethinyl estradiol as oral contraceptives.
Johansson ED; Elamsson K; Elmestedt U
Gynecol Obstet Invest; 1982; 14(2):97-105. PubMed ID: 6811379
[No Abstract] [Full Text] [Related]
40. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate.
Landgren BM; Johannisson E; Masironi B; Diczfalusy E
Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]